Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for Sedation after CABG
NCT06496165Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam in coronary artery disease (CAD) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Rate of hypotension during infusion at 8 hours. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06496165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496165.